Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Retained Earnings: 2014-2024

Historic Retained Earnings for Zevra Therapeutics (ZVRA) over the last 9 years, with Dec 2024 value amounting to -$505.3 million.

  • Zevra Therapeutics' Retained Earnings rose 7.53% to -$434.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$434.2 million, marking a year-over-year increase of 7.53%. This contributed to the annual value of -$505.3 million for FY2024, which is 26.39% down from last year.
  • Zevra Therapeutics' Retained Earnings amounted to -$505.3 million in FY2024, which was down 26.39% from -$399.8 million recorded in FY2023.
  • In the past 5 years, Zevra Therapeutics' Retained Earnings registered a high of -$258.5 million during FY2020, and its lowest value of -$505.3 million during FY2024.
  • Over the past 3 years, Zevra Therapeutics' median Retained Earnings value was -$399.8 million (recorded in 2023), while the average stood at -$419.6 million.
  • Data for Zevra Therapeutics' Retained Earnings shows a maximum YoY tumbled of 32.47% (in 2022) over the last 5 years.
  • Zevra Therapeutics' Retained Earnings (Yearly) stood at -$258.5 million in 2020, then fell by 3.31% to -$267.0 million in 2021, then slumped by 32.47% to -$353.7 million in 2022, then dropped by 13.02% to -$399.8 million in 2023, then dropped by 26.39% to -$505.3 million in 2024.